Emerging evidence · Grade B
GHRP-6
GHRP-6 Acetate (Growth Hormone Releasing Peptide-6)
Score
64 / 100
Class
GH-releasing peptide
Notable for
Appetite ↑
Status
Investigational
TL;DR
01
The original growth-hormone-releasing peptide — a synthetic hexapeptide that activates the ghrelin receptor to trigger GH release, first shown in humans in 1989.
02
It reliably raises growth hormone in people, but it is best known for strongly stimulating appetite, a direct ghrelin-like effect.
03
There are no trials showing it improves muscle, recovery, or aging — only that it releases GH.
04
It is less selective than newer secretagogues, so it can also raise cortisol and prolactin, and the GH response blunts with repeated use.
05
It is not an approved therapy; consumer supply is research-grade and unregulated.
Human GH release
Proven (1989)
dose-dependent, selective for GH
Appetite
Strongly ↑
ghrelin-like effect
Therapeutic RCTs
None
no clinical-benefit outcomes
Selectivity
Cortisol/prolactin ↑
less selective than newer GHRPs
Tolerance
GH response fades
with continued use
Part 01 · How it works
Mechanism.
GHRP-6 was the first of the GH-releasing peptides. Like ghrelin, it activates the pituitary's secretagogue receptor to release growth hormone — an effect confirmed in healthy men back in 1989. Its most reliable real-world effect, though, is hunger: it strongly stimulates appetite. As with the rest of the class, releasing GH is well documented, but whether repeated use produces any muscle or anti-aging benefit has never been tested, and the GH response diminishes over time.
The prototype 'GH release' button — it works, and it also flips on the hunger switch hard. Pressing it doesn't demonstrably build anything, and it answers less with repeated pressing.
GHS-R1a agonism
Agonist at the ghrelin receptor; His-DTrp-Ala-Trp-DPhe-Lys hexapeptide, the founding GHRP.
Appetite stimulation
Marked orexigenic (appetite-increasing) effect via ghrelin signaling.
Reduced selectivity
Can raise cortisol and prolactin alongside GH — less clean than ipamorelin.
Tachyphylaxis
GH response blunts with continued dosing.
Part 02 · Dosing & administration
How it's taken.
Community-reported · unregulatedValues below reflect commonly reported community protocols for GHRP-6. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Wk 1
100 mcg
Once nightly — start low to gauge the strong hunger response
TARGET
Wk 2–16
100 mcg 2–3×/day
Empty stomach; mimics pulsatile GH release. Community protocol, not clinical labeling.
·
Documented protocol is a Week-1 → Week-2+ titration; the top of the 100–300 mcg range exceeds the ~100 mcg saturation point.
·
Defining feature is a strong appetite spike (ghrelin mimetic); like all GHRPs it also raises prolactin/cortisol and desensitizes with continuous use.
·
No FDA-approved regimen; commonly stacked with a GHRH (CJC-1295) with no controlled combination data.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Increased appetite
The most prominent effect; ghrelin-like.
Strong
Flushing / head-rush
Transient.
Reported
Water retention
GH-axis effect.
Possible
Serious · rare
Cortisol / prolactin rise
Less selective than newer GHRPs.
Possible
IGF-1 / glucose effects
Chronic GH elevation carries insulin-resistance and mitogenic cautions.
Theoretical
Product-quality risk
Research-grade supply may not match labeled purity/dose.
Source-dependent
Absolute · do not use
×
Active malignancy or history of cancer
×
Pituitary tumor or hypothalamic disorders
×
Diabetic retinopathy
×
Pregnancy or breastfeeding
×
Children under 18 (unless for diagnosed GH deficiency under specialist care)
×
Known hypersensitivity to GHRP-6 or any component
×
Obesity with uncontrolled appetite (GHRP-6 strongly stimulates ghrelin/appetite)
Relative · discuss first
!
Active or prior malignancy — GH/IGF-1 mitogenic caution
!
Pregnancy or breastfeeding — no data
!
Diabetes or impaired glucose tolerance — GH raises insulin resistance
!
Those who don't want appetite stimulation — it is pronounced
Interactions
Insulin
GH secretagogues increase insulin resistance; may require insulin dose adjustment
Major
Oral hypoglycemics
GH elevation may counteract glucose-lowering effects
Moderate
Corticosteroids
Chronic corticosteroid use blunts GH release and may reduce GHRP-6 efficacy
Moderate
Appetite suppressants
GHRP-6 strongly stimulates appetite via ghrelin mimicry, directly opposing appetite suppressant effects
Moderate
Labs to monitor
IGF-1
Baseline, 4 weeks, then every 3 months
Monitor growth hormone axis stimulation
Fasting Glucose & Insulin
Baseline and monthly
GH can impair insulin sensitivity
Prolactin
Baseline and at 4 weeks
GHRP-6 can modestly elevate prolactin
Cortisol (AM)
Baseline and at 4 weeks
GHRP-6 stimulates cortisol release
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
Part 04 · Evidence
How strong is the evidence?
64
Grade B
Grade B, Emerging. Foundational, reproducible human GH-release data — but no therapeutic outcome trials, strong appetite stimulation, off-target hormone effects, and a fading response temper the picture.
Mechanistic plausibility
The original, well-mapped GHRP mechanism.
78
Human evidence
Clear human GH-release data since 1989; no therapeutic efficacy trials.
55
Safety & tolerability
Short-term tolerated but marked appetite increase and cortisol/prolactin effects; long-term data limited.
62
Durability
GH response diminishes with continued use.
52
Independence
GH-release effect replicated across groups over decades.
64
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
1989
J Clin Endocrinol Metab Flagged
A new synthetic hexapeptide selectively stimulates GH release in healthy humans
Produced a dramatic, dose-dependent, selective rise in GH (no change in LH/FSH/TSH/ACTH) and was safe and well tolerated — the founding human demonstration of the GHRP class.
Dose-ranging IV infusion vs saline in healthy men · n = 17 · Acute GH-release study; does not address chronic therapeutic use.
PMID 2543692 ↗
Moderate
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
Releases GH — but nothing beyond that is proven
Mechanism limit JCEM · 1989
Decades after its discovery, GHRP-6's human evidence still amounts to reliable acute GH release. No trial has shown that repeated use improves muscle, recovery, body composition, or aging.
What this means: A proven GH-release effect is not proof of benefit. The marketed muscle/recovery uses rest on inference, not outcomes.
PMID 2543692 ↗
02
Strong appetite stimulation, off-target hormones, and tolerance
Mechanism limit class pharmacology · 1989
GHRP-6 strongly increases appetite and, being less selective, can raise cortisol and prolactin; the GH response blunts with continued dosing.
What this means: For anyone not seeking appetite stimulation, the side-effect and tachyphylaxis profile makes chronic use hard to justify.
PMID 2543692 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Not approved
No approved product; sold as a research chemical. No legal consumer medicine.
Grey-market; unregulated
European Union
Not approved
No approved product.
N/A
United Kingdom
Not approved
No approved product.
N/A
Canada
Not approved
No approved product.
N/A
The Peptide Column takes no affiliate commission from any source. GHRP-6 is not an approved therapy; consumer supply is research-grade and unregulated, and its muscle/recovery benefits are unproven. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
Will the appetite-stimulating effects of GHRP-6 be beneficial or problematic for my goals?
02
How does GHRP-6 compare to GHRP-2 or ipamorelin in terms of side effects?
03
What labs should I monitor (IGF-1, glucose, cortisol, prolactin)?
04
Is GHRP-6 appropriate if I have insulin resistance or diabetes risk?
05
What is the recommended dosing frequency and cycle length?
06
Should I combine GHRP-6 with a GHRH analog?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. A new synthetic hexapeptide selectively stimulates GH release in healthy humans · J Clin Endocrinol Metab, 1989 · PMID 2543692 ↗
- 02. PubMed. GHRP-6 GH-release literature (since 1989)